How Can Herpes Zoster Events Be Managed in Patients With RA and PsA Receiving Tofacitinib?
Researchers evaluated the management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis receiving tofacitinib treatment.
Psoriatic Arthritis
Dactylitis – A Clinical Marker for a More Severe Phenotype in DMARD-Naive Early PsA
Dactylitis denotes a more severe disease phenotype independently associated with greater swollen joint counts, CRP, and synovitis in DMARD-naive early PsA.
Serum Biomarkers Can Differentiate Psoriatic Arthritis, Rheumatoid Arthritis
A serum protein biomarker panel can differentiate patients with early inflammatory arthritis with psoriatic arthritis from those with rheumatoid arthritis.
Outcomes of COVID-19 in Patients With Autoimmune Conditions Receiving Systemic Therapies
Researchers assessed the characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis who were receiving systemic therapies.
Secukinumab Approved for Enthesitis-Related Arthritis, Juvenile Psoriatic Arthritis
The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA.
Early Screening and Management of Cardiovascular Risk Factors Important in Psoriatic Arthritis and Ankylosing Spondylitis
Authors of the systematic review and meta-analysis aimed to determine the all-cause and cause-specific mortality in psoriatic arthritis and ankylosing spondylitis, based on available literature.
Upadacitinib Approved for Active Psoriatic Arthritis
The application is supported by data from two phase 3 studies (SELECT-PsA 1 and SELECT-PsA 2) that assessed upadacitinib in adults with active PsA.
Significant Improvements With Risankizumab in Patients With Psoriatic Arthritis
KEEPSAKE 2 is a clinical trial evaluating the efficacy and safety of risankizumab in patients with psoriatic arthritis.
Effect of the COVID-19 Pandemic on Psoriatic Disease
The effect of the COVID-29 pandemic on the hospital admissions and treatment adherences of patients with psoriasis are examined.
Guselkumab Improves Psoriatic Arthritis in Patients With Inadequate Response to TNFi
The phase 3 COSMOS study evaluated the efficacy and safety of guselkumab in 285 adults with active PsA who had an inadequate response to anti-tumor necrosis factors.
- Loading...
Loading...
Next post in Psoriatic Arthritis
Loading... 
Loading...